May 14, 2018
IKARpro – the number of new active substances on reimbursement in Poland
Ikarpro.pl – it is an innovative service which combines:
- quick access to reimbursement databases
- broad range of analytical tools
- easy to be found important information.
IKAR pro is a platform allowing for quick access to up-to-date data on reimbursed drugs. The platform facilitates complex analyses on reimbursement data in Poland.
Based on data from the IKARpro database, we present information on the number of new active substances on reimbursement in Poland (A – Outpatient List, B – Drug Programmes, C – Chemotherapy) from the entry into force of the Reimbursement Act.
The number of new active substances allowed for reimbursement is growing year by year, mainly as part of drug programmes (B), in oncology. The decreasing number of completely new active substances on the list of prescription drugs (A) is significant.
Source: data from ikarpro.pl